Hsia J et al. J Am Coll Cardiol 2011;57:1666-75
description
Transcript of Hsia J et al. J Am Coll Cardiol 2011;57:1666-75
![Page 1: Hsia J et al. J Am Coll Cardiol 2011;57:1666-75](https://reader036.fdocuments.in/reader036/viewer/2022062301/56815e2f550346895dcc8ade/html5/thumbnails/1.jpg)
Hsia J et al. J Am Coll Cardiol 2011;57:1666-75
![Page 2: Hsia J et al. J Am Coll Cardiol 2011;57:1666-75](https://reader036.fdocuments.in/reader036/viewer/2022062301/56815e2f550346895dcc8ade/html5/thumbnails/2.jpg)
Baseline Characteristics by Treatment Group and Attained LDL-C
Hsia J et al. J Am Coll Cardiol 2011;57:1666-75
![Page 3: Hsia J et al. J Am Coll Cardiol 2011;57:1666-75](https://reader036.fdocuments.in/reader036/viewer/2022062301/56815e2f550346895dcc8ade/html5/thumbnails/3.jpg)
Independent Predictors of Attaining LDL-C <50 mg/dl at Any Visit Among
Rosuvastatin-Allocated Patients
Hsia J et al. J Am Coll Cardiol 2011;57:1666-75
![Page 4: Hsia J et al. J Am Coll Cardiol 2011;57:1666-75](https://reader036.fdocuments.in/reader036/viewer/2022062301/56815e2f550346895dcc8ade/html5/thumbnails/4.jpg)
Cardiovascular Events and All-Cause Mortality by Baseline LDL-C Level
Hsia J et al. J Am Coll Cardiol 2011;57:1666-75
![Page 5: Hsia J et al. J Am Coll Cardiol 2011;57:1666-75](https://reader036.fdocuments.in/reader036/viewer/2022062301/56815e2f550346895dcc8ade/html5/thumbnails/5.jpg)
Time to Occurrence of Major Cardiovascular Events According to Treatment Group and Achieved LDL-C Concentrations
Hsia J et al. J Am Coll Cardiol 2011;57:1666-75
![Page 6: Hsia J et al. J Am Coll Cardiol 2011;57:1666-75](https://reader036.fdocuments.in/reader036/viewer/2022062301/56815e2f550346895dcc8ade/html5/thumbnails/6.jpg)
Primary Endpoint in Pre-Specified Subgroups Within JUPITER Trial, Stratified by Achieved LDL-C
Hsi
a J
et a
l. J
Am
Col
l Car
diol
201
1;57
:166
6-75
![Page 7: Hsia J et al. J Am Coll Cardiol 2011;57:1666-75](https://reader036.fdocuments.in/reader036/viewer/2022062301/56815e2f550346895dcc8ade/html5/thumbnails/7.jpg)
Fully-Adjusted Hazard Ratios for Incident Cardiovascular Events and All-Cause Mortality According to Treatment
Group and Achieved Concentrations of LDL-C
Hsia J et al. J Am Coll Cardiol 2011;57:1666-75
![Page 8: Hsia J et al. J Am Coll Cardiol 2011;57:1666-75](https://reader036.fdocuments.in/reader036/viewer/2022062301/56815e2f550346895dcc8ade/html5/thumbnails/8.jpg)
Numbers and Rates (per 100 Person-Years) of Treatment-Emergent Adverse Events by Treatment Group and Attained LDL-C
Hsia J et al. J Am Coll Cardiol 2011;57:1666-75
![Page 9: Hsia J et al. J Am Coll Cardiol 2011;57:1666-75](https://reader036.fdocuments.in/reader036/viewer/2022062301/56815e2f550346895dcc8ade/html5/thumbnails/9.jpg)
ALT or CK Elevation, Proteinuria, or Hematuria at Any Follow-Up Visit by Treatment Assignment and Attained LDL-C
Hsia J et al. J Am Coll Cardiol 2011;57:1666-75
![Page 10: Hsia J et al. J Am Coll Cardiol 2011;57:1666-75](https://reader036.fdocuments.in/reader036/viewer/2022062301/56815e2f550346895dcc8ade/html5/thumbnails/10.jpg)
Relation of Major Cardiovascular Event Rate to LDL-C at 1 Year in Primary Prevention Trials
Hsia J et al. J Am Coll Cardiol 2011;57:1666-75